← 產業報告目錄

Preimplantation Genetic Testing Market by Product & Service (Reagents, Consumables, Instruments, Software), Technology (NGS, PCR, SNP, CGH), Procedure (Screening, Diagnosis), Application (Aneuploidy, HLA Typing), Type of cycle - Global Forecast to 2030

出版商 MarketsandMarkets產業別 Healthcare & Life Sciences出版日期 2025-11-07頁數 415報告編號 BT5411

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The preimplantation genetic testing market is expected to reach USD 1,135.0 million by 2030, up from USD 690.2 million in 2025, at a CAGR of 10.5% during the forecast period. The market growth is primarily driven by the increasing prevalence of genetic disorders, growing awareness regarding early genetic diagnosis, and the rising adoption of in-vitro fertilization (IVF) procedures worldwide. The demand for preimplantation genetic testing is also supported by advancements in next-generation sequencing (NGS) and polymerase chain reaction (PCR) technologies that enhance testing accuracy and efficiency. Moreover, the growing trend toward delayed pregnancies and the rising risk of chromosomal abnormalities in embryos are contributing to the market expansion. However, the high costs associated with IVF and genetic testing procedures, along with ethical and regulatory challenges, continue to hinder widespread adoption. “The aneuploidy application segment is expected to grow at the highest CAGR during the forecast period.” The aneuploidy application segment is projected to grow at the highest CAGR in the preimplantation genetic testing market during the forecast period. This growth is primarily driven by the rising incidence of chromosomal abnormalities, particularly among women of advanced maternal age, and the increasing demand for accurate embryo screening in IVF procedures. Aneuploidy enables the detection of abnormal chromosome numbers, helping improve implantation rates and reduce the risk of miscarriage. The integration of advanced genomic tools such as next-generation sequencing (NGS) and array-based comparative genomic hybridization (aCGH) has further enhanced test precision and efficiency. Additionally, growing awareness of genetic screening benefits and the rising adoption of assisted reproductive technologies are contributing to the strong growth of the aneuploidy segment globally. “The reagents and consumables segment holds the largest share of the market.” The reagents and consumables segment holds the largest share of the preimplantation genetic testing market. This dominance is due to their repeated use at every stage of the testing process, including sample preparation, amplification, and analysis. The increasing number of IVF procedures and genetic tests has greatly boosted the demand for high-quality reagents, assay kits, and consumables that provide accuracy, reproducibility, and consistent results. Additionally, advances in next-generation sequencing (NGS), polymerase chain reaction (PCR), and array-based platforms have enabled the development of specialized reagents for high-throughput and precise embryo analysis. Ongoing product innovations by major market players, along with the growing use of genetic screening in fertility clinics and research labs, further drive segment growth. The essential and recurring nature of these products secures their leading role in the global preimplantation genetic testing market. “The US is expected to grow at the highest CAGR during the forecast period.” The US is expected to have the highest growth rate in the preimplantation genetic testing market, driven by several key factors. The strong presence of leading IVF clinics, advanced genomic labs, and a well-established healthcare system significantly contributes to market growth in the country. Additionally, the increasing rate of infertility, rising average maternal age, and growing awareness of genetic screening options are boosting demand for preimplantation genetic testing in the US. Favorable reimbursement policies, supportive government initiatives for reproductive health, and ongoing investments in genomic research further drive market expansion. Furthermore, the growing integration of next-generation sequencing (NGS) and polymerase chain reaction (PCR) technologies in IVF procedures is improving testing accuracy and efficiency. Increasing access to assisted reproductive technologies, along with the rising preference for personalized reproductive care, continues to drive the adoption of preimplantation genetic testing across the region. The US’s robust regulatory framework ensures test reliability and clinical validity, bolstering confidence in preimplantation genetic testing solutions and reinforcing North America’s leading position in the global market. The primary interviews conducted for this report can be categorized as follows: • By Respondent: Tier 1 – 25%, Tier 2 – 35%, and Tier 3 – 40% • By Designation: Managers – 45%, CXOs and Directors – 30%, and Executives – 25% • By Region: North America – 35%, Europe – 25%, Asia Pacific – 15%, Latin America – 10%, the Middle East – 10%, and Africa – 5% Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Revvity (US), CooperCompanies (US), Abbott (US), Takara Bio Inc. (Japan), QIAGEN (Germany), Vitrolife (Sweden), Oxford Nanopore Technologies plc (UK), Oxford Gene Technology IP Limited (UK), Yikon Genomics (China), Shiva Scientific (India), Nanjing Superyears Gene Technology Co. Ltd. (China), Medicover Genetics (Germany), MedGenome (India), Fulgent Genetics (US), Invicta (Poland), Genea Pty Limited (Australia), SciGene Corporation (US), Bioarray S.L. (Spain), Unimed Biotech (Shanghai) Co., Ltd. (China), GeneMind Biosciences Co. Ltd. (China), Berry Genomics (China), and Bangkok Genomics Innovation (Thailand) are some of the key companies offering preimplantation genetic testing products. Research Coverage This research report categorizes the preimplantation genetic testing market by procedure type (preimplantation genetic screening, preimplantation genetic diagnosis), technology (next-generation sequencing, polymerase chain reaction, fluorescence in situ hybridization, comparative genomic hybridization, single-nucleotide polymorphism), product & service (reagents & consumables, instruments, software & services), application (aneuploidy, structural chromosomal abnormalities [translocations, deletions, duplications, inversions], single gene disorders, X-linked disorders, HLA typing, gender identification), type of cycle (fresh non-donor, frozen non-donor, fresh donor, frozen donor), end user (fertility clinics, hospitals, diagnostic laboratories, other end users), and region (North America, Europe, Asia Pacific, Latin America, Middle East, And Africa). The report’s scope encompasses detailed information about the primary factors, including drivers, restraints, challenges, and opportunities, that influence the growth of the preimplantation genetic testing market. A comprehensive analysis of key industry players has been performed to provide insights into their business overview, product portfolio, key strategies, new product launches, acquisitions, and recent developments related to the preimplantation genetic testing market. This report also includes a competitive analysis of emerging startups in the preimplantation genetic testing industry ecosystem. Key Benefits of Buying the Report The report will assist market leaders and new entrants by providing revenue estimates for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market's pulse and offer information on key market drivers, restraints, opportunities, and challenges. The report provides insights into the following pointers: • Analysis of key drivers (decline in fertility, rise of fertility tourism in emerging economies, increasing number of fertility clinics and IVF centers, increasing public-private investments to develop novel diagnostic techniques, and high risk of chromosomal abnormalities with advancing maternal age), restraints (high procedural cost in preimplantation genetic testing and unfavorable government regulations and healthcare reforms for IVF procedures), opportunities (improving healthcare infrastructure and rising medical tourism in emerging economies and use of fertility treatments by single parents and same-sex couples), and challenges (socio-ethical concerns surrounding preimplantation genetic testing and procedural limitations with advancing age) influencing the market growth • Product Development/Innovation: Detailed insights into newly launched products and technological assessment of the preimplantation genetic testing market • Market Development: Comprehensive information about lucrative markets and analysis of the market across varied regions • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the preimplantation genetic testing market • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players, including Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), and Agilent Technologies, Inc. (US), Revvity (US), CooperCompanies (US), and Abbott (US), among others offering products and services for preimplantation genetic testing market. Other companies include MedGenome (India), Fulgent Genetics (US), Invicta (Poland), Genea Pty Limited (Australia), SciGene Corporation (US), Bioarray S.L. (Spain), Unimed Biotech (Shanghai) Co., Ltd (China), and GeneMind Biosciences Co., Ltd. (China), among others, for the preimplantation genetic testing market
目錄 Table of Contents
1 INTRODUCTION 36 1.1 STUDY OBJECTIVES 36 1.2 MARKET DEFINITION 36 1.3 STUDY SCOPE 37 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 37 1.3.2 INCLUSIONS & EXCLUSIONS 38 1.3.3 YEARS CONSIDERED 38 1.3.4 CURRENCY CONSIDERED 39 1.4 STAKEHOLDERS 39 1.5 SUMMARY OF CHANGES 39 2 EXECUTIVE SUMMARY 41 2.1 KEY INSIGHTS & MARKET HIGHLIGHTS 41 2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS 48 2.3 DISRUPTIVE TRENDS SHAPING PREIMPLANTATION GENETIC TESTING MARKET 49 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 49 2.5 GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SNAPSHOT 50 3 PREMIUM INSIGHTS 51 3.1 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE AND COUNTRY 51 3.2 PREIMPLANTATION GENETIC TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 52 3.3 PREIMPLANTATION GENETIC TESTING MARKET SHARE, BY PRODUCT & SERVICE, 2025 VS. 2030 (%) 53 3.4 PREIMPLANTATION GENETIC TESTING MARKET SHARE, BY END USER, 2024 (%) 53 4 MARKET OVERVIEW 54 4.1 INTRODUCTION 54 4.2 MARKET DYNAMICS 54 4.2.1 DRIVERS 55 4.2.1.1 Decline in fertility rates 55 4.2.1.2 Expanding network of fertility clinics and IVF centers 56 4.2.1.3 Rising incidence of chromosomal abnormalities associated with advancing maternal age 56 4.2.2 RESTRAINTS 57 4.2.2.1 High procedural cost 57 4.2.2.2 Stringent regulatory frameworks governing IVF and genetic testing procedures 57   4.2.3 OPPORTUNITIES 58 4.2.3.1 Expanding acceptance of fertility treatments among single parents and same-sex couples 58 4.2.4 CHALLENGES 58 4.2.4.1 Socio-ethical concerns regarding embryo screening and selection 58 4.3 UNMET NEEDS & WHITE SPACES 59 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 59 4.5 STRATEGIC MOVIES BY TIER-1/2/3 PLAYERS 60 5 INDUSTRY TRENDS 62 5.1 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 62 5.2 MACROECONOMIC OUTLOOK 62 5.2.1 GDP TRENDS & FORECAST 63 5.2.2 R&D TRENDS IN GLOBAL HEALTHCARE INDUSTRY 63 5.2.3 R&D TRENDS IN GLOBAL PHARMA INDUSTRY 63 5.3 CASE STUDY ANALYSIS 64 5.3.1 PGT-M FOR RPGRIP1L VARIANT-ENABLED BY MINIGENE ASSAY 64 5.3.2 PERSISTENT FETAL MOSAICISM AFTER TRANSFER OF PGT-A MOSAIC EMBRYO 64 5.3.3 CRYPTIC REARRANGEMENTS RESOLVED BY OGM TO GUIDE PGT-SR 64 5.4 PRICING ANALYSIS 64 5.4.1 AVERAGE SELLING PRICE TREND OF PREIMPLANTATION GENETIC TESTING PRODUCTS, BY END USER, 2022−2024 65 5.4.2 AVERAGE SELLING PRICE TREND OF PREIMPLANTATION GENETIC TESTING PRODUCTS, BY KEY PLAYER, 2022–2024 65 5.4.3 AVERAGE SELLING PRICE TREND OF PREIMPLANTATION GENETIC TESTING PRODUCTS, BY PROCEDURE TYPE, 2022−2024 67 5.4.4 AVERAGE SELLING PRICE TREND OF PREIMPLANTATION GENETIC TESTING INSTRUMENTS AND CONSUMABLES, BY REGION, 2022–2024 67 5.5 TRADE ANALYSIS 69 5.5.1 IMPORT DATA FOR HS CODE 3822, 2020–2024 69 5.5.2 EXPORT DATA FOR HS CODE 3822, 2020–2024 70 5.5.3 IMPORT DATA FOR HS CODE 9018, 2020–2024 71 5.5.4 EXPORT DATA FOR HS CODE 9018, 2020–2024 72 5.6 VALUE CHAIN ANALYSIS 72 5.7 ECOSYSTEM ANALYSIS 74 5.7.1 ROLE IN ECOSYSTEM 76 5.8 PORTER’S FIVE FORCES ANALYSIS 77 5.8.1 INTENSITY OF COMPETITIVE RIVALRY 78 5.8.2 BARGAINING POWER OF SUPPLIERS 78 5.8.3 BARGAINING POWER OF BUYERS 78 5.8.4 THREAT OF SUBSTITUTES 78 5.8.5 THREAT OF NEW ENTRANTS 78   5.9 KEY CONFERENCES & EVENTS, 2025–2026 79 5.10 INVESTMENT & FUNDING SCENARIO 80 5.11 IMPACT OF 2025 US TARIFF ON PREIMPLANTATION GENETIC TESTING MARKET 81 5.11.1 KEY TARIFF RATES 81 5.11.2 PRICE IMPACT ANALYSIS 83 5.11.3 KEY IMPACTS ON VARIOUS REGIONS 84 5.11.3.1 US 84 5.11.3.2 Europe 84 5.11.3.3 Asia Pacific 85 5.11.4 END-USE INDUSTRY IMPACT 85 5.11.4.1 Fertility clinics 85 5.11.4.2 Hospitals 85 5.11.4.3 Diagnostic laboratories 86 6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 87 6.1 TECHNOLOGY ANALYSIS 87 6.1.1 KEY TECHNOLOGIES 87 6.1.1.1 Laser-assisted TE biopsy 87 6.1.1.2 Whole genome amplification 87 6.1.2 COMPLEMENTARY TECHNOLOGIES 88 6.1.2.1 Micromanipulation 88 6.2 TECHNOLOGY ROADMAP 88 6.3 PATENT ANALYSIS 89 6.3.1 METHODOLOGY 89 6.3.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE 89 6.3.3 LIST OF KEY PATENTS 91 6.4 FUTURE APPLICATIONS 91 6.5 IMPACT OF AI/GEN AI ON PREIMPLANTATION GENETIC TESTING MARKET 92 6.5.1 TOP USE CASES AND MARKET POTENTIAL 93 6.5.2 BEST PRACTICES IN AI-ENABLED EMBRYO SELECTION AND GENETIC SCREENING 94 6.5.3 CASE STUDIES OF AI IMPLEMENTATION IN PREIMPLANTATION GENETIC TESTING MARKET 94 6.5.4 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS 95 6.5.5 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN PREIMPLANTATION GENETIC TESTING MARKET 95   7 SUSTAINABILITY & REGULATORY LANDSCAPE 96 7.1 REGIONAL REGULATIONS & COMPLIANCE 96 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES & OTHER ORGANIZATIONS 96 7.1.2 INDUSTRY STANDARDS 99 7.1.2.1 North America 99 7.1.2.1.1 US 99 7.1.2.1.2 Canada 101 7.1.2.2 Europe 102 7.1.2.3 Asia Pacific 104 7.1.2.3.1 Japan 104 7.1.2.3.2 China 106 7.1.2.3.3 India 106 7.1.2.4 Latin America 107 7.1.2.4.1 Brazil 107 7.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 108 7.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 109 8 CUSTOMER LANDSCAPE & BUYER BEHAVIOUR 110 8.1 DECISION-MAKING PROCESS 110 8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 110 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 110 8.2.2 KEY BUYING CRITERIA 111 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 113 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 113 9 PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE 114 9.1 INTRODUCTION 115 9.2 REAGENTS & CONSUMABLES 115 9.2.1 EXPANSION OF ADVANCED GENOMIC TECHNOLOGIES TO PROMOTE MARKET GROWTH 115 9.3 INSTRUMENTS 119 9.3.1 ONGOING TECHNOLOGICAL ADVANCEMENTS AND INCREASING FERTILITY CLINICS TO PROPEL MARKET GROWTH 119 9.4 SOFTWARE & SERVICES 123 9.4.1 RISING AWARENESS ABOUT DATA ANALYSIS TO DRIVE MARKET 123 10 PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE 128 10.1 INTRODUCTION 129 10.2 PREIMPLANTATION GENETIC SCREENING 129 10.2.1 INCREASING MATERNAL AGE TO AID MARKET GROWTH 129 10.3 PREIMPLANTATION GENETIC DIAGNOSIS 133 10.3.1 RISING AWARENESS ABOUT CHROMOSOMAL ABNORMALITIES IN FETUSES TO SUPPORT MARKET GROWTH 133 11 PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY 138 11.1 INTRODUCTION 139 11.2 NEXT-GENERATION SEQUENCING 139 11.2.1 IMPROVED TECHNOLOGY FOR DETECTING STRUCTURAL ABNORMALITIES TO FUEL MARKET GROWTH 139 11.3 POLYMERASE CHAIN REACTION 143 11.3.1 INCREASED USAGE IN CLINICAL AND RESEARCH APPLICATIONS AND HIGH PREVALENCE OF GENETIC DISEASES TO SUPPORT MARKET 143 11.4 FLUORESCENCE IN SITU HYBRIDIZATION 147 11.4.1 ADVANCES IN FLUORESCENCE MICROSCOPY AND DIGITAL IMAGING TO AUGMENT MARKET GROWTH 147 11.5 COMPARATIVE GENOMIC HYBRIDIZATION 151 11.5.1 LOW COST, LESS LABOR REQUIREMENT, AND ONGOING TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET 151 11.6 SINGLE-NUCLEOTIDE POLYMORPHISM 155 11.6.1 HIGH-RESOLUTION ACCURACY AND VALIDATED CLINICAL PERFORMANCE TO BOOST MARKET GROWTH 155 12 PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION 160 12.1 INTRODUCTION 161 12.2 ANEUPLOIDY 161 12.2.1 HIGH ANEUPLOIDY INCIDENCE AND RAPID INNOVATION TO ACCELERATE MARKET GROWTH 161 12.3 STRUCTURAL CHROMOSOMAL ABNORMALITIES 165 12.3.1 TRANSLOCATIONS 169 12.3.1.1 Rising incidence of translocation chromosomal abnormalities during IVF treatments to drive segment 169 12.3.2 DELETIONS 173 12.3.2.1 Advancements in genetic testing to boost segment growth 173 12.3.3 DUPLICATIONS 177 12.3.3.1 Rising cases of duplication of chromosomal abnormalities and increasing maternal age to drive segment 177 12.3.4 INVERSIONS 181 12.3.4.1 Risk of unexplained male‐factor infertility and multiple miscarriages to limit segment growth 181 12.4 SINGLE GENE DISORDERS 185 12.4.1 INCREASING AWARENESS ABOUT GENETIC TESTING TO PROPEL MARKET GROWTH 185 12.5 X-LINKED DISORDERS 189 12.5.1 MEDICAL ADVANCEMENTS AND INCREASED RESEARCH ON GENETIC DISORDERS TO AUGMENT MARKET GROWTH 189 12.6 HLA TYPING 193 12.6.1 RISING NUMBER OF COUPLES WITH CHILDREN AFFECTED BY HEMATOLOGICAL DISEASES TO DRIVE MARKET 193   12.7 GENDER IDENTIFICATION 197 12.7.1 INCREASED FOCUS ON SEX DISCRIMINATION TO LIMIT MARKET GROWTH 197 13 PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE 202 13.1 INTRODUCTION 203 13.2 FRESH NON-DONOR 203 13.2.1 HIGH RATES OF SUCCESSFUL PREGNANCY AMONG YOUNG WOMEN TO DRIVE MARKET GROWTH 203 13.3 FROZEN NON-DONOR 207 13.3.1 LONG-TERM STORAGE OF FROZEN EGGS AND EASY SCHEDULING TO PROPEL MARKET GROWTH 207 13.4 FRESH DONOR 211 13.4.1 HIGH-QUALITY FRESH DONOR OOCYTES AND EXPANDING PGT-DRIVEN RISK REDUCTION TO PROMOTE MARKET GROWTH 211 13.5 FROZEN DONOR 215 13.5.1 RISING USE OF ADVANCED AND NON-INVASIVE PGT TECHNOLOGIES TO AID MARKET GROWTH 215 14 PREIMPLANTATION GENETIC TESTING MARKET, BY END USER 220 14.1 INTRODUCTION 221 14.2 FERTILITY CLINICS 221 14.2.1 HIGH SUCCESS RATE OF FERTILITY TREATMENT TO DRIVE MARKET 221 14.3 DIAGNOSTIC LABORATORIES 225 14.3.1 IMPROVED CLINICAL EFFICACY AND INCREASED RESEARCH FUNDING TO FUEL MARKET 225 14.4 HOSPITALS 229 14.4.1 RISING NUMBER OF HOSPITALS AND INCREASING HEALTHCARE AWARENESS TO DRIVE GROWTH 229 14.5 OTHER END USERS 233 15 PREIMPLANTATION GENETIC TESTING MARKET, BY REGION 238 15.1 INTRODUCTION 239 15.2 NORTH AMERICA 239 15.2.1 US 244 15.2.1.1 US to dominate North American preimplantation genetic testing market during forecast period 244 15.2.2 CANADA 248 15.2.2.1 Whole-genome embryo testing and public-private R&D investment to propel market growth 248 15.3 EUROPE 252 15.3.1 GERMANY 257 15.3.1.1 Global clinical adoption of precision medicines to boost market growth 257 15.3.2 UK 261 15.3.2.1 Demographic pressures and evidence-based clinical innovation to support market growth 261 15.3.3 FRANCE 265 15.3.3.1 Ethical regulation and adoption of patient-centered precision medicines to fuel market growth 265 15.3.4 ITALY 268 15.3.4.1 Regulatory reforms and clinical-genetic partnerships to boost market growth 268 15.3.5 SPAIN 272 15.3.5.1 Well-established network of research centers and universities to augment market growth 272 15.3.6 REST OF EUROPE 276 15.4 ASIA PACIFIC 280 15.4.1 CHINA 285 15.4.1.1 Advancing next-generation genomic infrastructure and cross-border fertility capacity to propel market growth 285 15.4.2 JAPAN 289 15.4.2.1 Reinforcing global PGT standards and rigorous clinical governance to favor market growth 289 15.4.3 INDIA 293 15.4.3.1 Expanding genetic-diagnostic access to drive market growth 293 15.4.4 AUSTRALIA 297 15.4.4.1 Standardized regulation and expanding clinical adoption to fuel market growth 297 15.4.5 SOUTH KOREA 301 15.4.5.1 Clinically validated PGT-A integration and improved IVF outcomes to support market growth 301 15.4.6 REST OF ASIA PACIFIC 305 15.5 LATIN AMERICA 309 15.5.1 BRAZIL 313 15.5.1.1 Global genomic innovation and regulatory modernization to boost market growth 313 15.5.2 MEXICO 317 15.5.2.1 Adoption of advanced NGS-based PGT services to support growth 317 15.5.3 REST OF LATIN AMERICA 321 15.6 MIDDLE EAST 325 15.6.1 GCC COUNTRIES 329 15.6.1.1 Kingdom of Saudi Arabia 334 15.6.1.1.1 Rising global emphasis on preventive genomic medicine and advanced embryo-screening technologies to drive market 334 15.6.1.2 UAE 338 15.6.1.2.1 Rising global demand for safer and technologically advanced embryo screening to aid market growth 338 15.6.1.3 Rest of GCC Countries 342   15.6.2 REST OF MIDDLE EAST 345 15.7 AFRICA 349 15.7.1 REGIONAL ART REGISTRY EXPANSION AND RISING IVF INFRASTRUCTURE TO PROPEL MARKET GROWTH 349 16 COMPETITIVE LANDSCAPE 354 16.1 INTRODUCTION 354 16.2 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PREIMPLANTATION GENETIC TESTING MARKET 354 16.3 REVENUE ANALYSIS, 2020–2024 355 16.4 MARKET SHARE ANALYSIS, 2024 356 16.5 COMPANY VALUATION & FINANCIAL METRICS 358 16.5.1 FINANCIAL METRICS 358 16.5.2 COMPANY VALUATION 358 16.6 BRAND/PRODUCT COMPARISON 359 16.6.1 ILLUMINA, INC. 360 16.6.2 THERMO FISHER SCIENTIFIC INC. 360 16.6.3 AGILENT TECHNOLOGIES, INC. 360 16.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 360 16.7.1 STARS 360 16.7.2 EMERGING LEADERS 360 16.7.3 PERVASIVE PLAYERS 361 16.7.4 PARTICIPANTS 361 16.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 362 16.7.5.1 Company footprint 362 16.7.5.2 Region footprint 363 16.7.5.3 Product & service footprint 363 16.7.5.4 Technology footprint 364 16.7.5.5 Application footprint 365 16.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 366 16.8.1 PROGRESSIVE COMPANIES 366 16.8.2 RESPONSIVE COMPANIES 366 16.8.3 DYNAMIC COMPANIES 366 16.8.4 STARTING BLOCKS 366 16.8.5 COMPETITIVE BENCHMARKING 368 16.8.5.1 Detailed list of key startups/SMEs 368 16.8.5.2 Competitive benchmarking of key startups/SMEs 370 16.9 COMPETITIVE SCENARIO 371 16.9.1 PRODUCT LAUNCHES 371 16.9.2 DEALS 371 16.9.3 EXPANSIONS 372   17 COMPANY PROFILES 373 17.1 KEY PLAYERS 373 17.1.1 ILLUMINA, INC. 373 17.1.1.1 Business overview 373 17.1.1.2 Products/Services/Solutions offered 374 17.1.1.3 Recent developments 375 17.1.1.3.1 Deals 375 17.1.1.4 MnM view 375 17.1.1.4.1 Key strengths 375 17.1.1.4.2 Strategic choices 375 17.1.1.4.3 Weaknesses & competitive threats 375 17.1.2 THERMO FISHER SCIENTIFIC INC. 376 17.1.2.1 Business overview 376 17.1.2.2 Products/Services/Solutions offered 377 17.1.2.3 Recent developments 378 17.1.2.3.1 Product launches 378 17.1.2.4 MnM view 378 17.1.2.4.1 Key strengths 378 17.1.2.4.2 Strategic choices 378 17.1.2.4.3 Weaknesses & competitive threats 378 17.1.3 AGILENT TECHNOLOGIES, INC. 379 17.1.3.1 Business overview 379 17.1.3.2 Products/Services/Solutions offered 380 17.1.3.3 MnM view 381 17.1.3.3.1 Key strengths 381 17.1.3.3.2 Strategic choices 381 17.1.3.3.3 Weaknesses & competitive threats 381 17.1.4 REVVITY 382 17.1.4.1 Business overview 382 17.1.4.2 Products/Services/Solutions offered 383 17.1.4.3 MnM view 384 17.1.4.3.1 Key strengths 384 17.1.4.3.2 Strategic choices 384 17.1.4.3.3 Weaknesses & competitive threats 384 17.1.5 COOPERCOMPANIES 385 17.1.5.1 Business overview 385 17.1.5.2 Products/Services/Solutions offered 386 17.1.5.3 MnM view 387 17.1.5.3.1 Key strengths 387 17.1.5.3.2 Strategic choices 387 17.1.5.3.3 Weaknesses & competitive threats 387   17.1.6 ABBOTT 388 17.1.6.1 Business overview 388 17.1.6.2 Products/Services/Solutions offered 389 17.1.7 TAKARA BIO INC. 390 17.1.7.1 Business overview 390 17.1.7.2 Products/Services/Solutions offered 391 17.1.8 QIAGEN 392 17.1.8.1 Business overview 392 17.1.8.2 Products/Services/Solutions offered 393 17.1.9 VITROLIFE 394 17.1.9.1 Business overview 394 17.1.9.2 Products/Services/Solutions offered 395 17.1.10 OXFORD NANOPORE TECHNOLOGIES PLC 396 17.1.10.1 Business overview 396 17.1.10.2 Products/Services/Solutions offered 397 17.1.10.3 Recent developments 398 17.1.10.3.1 Expansions 398 17.2 OTHER PLAYERS 398 17.2.1 OXFORD GENE TECHNOLOGY IP LIMITED 398 17.2.2 YIKON GENOMICS 399 17.2.3 SHIVA SCIENTIFIC 399 17.2.4 NANJING SUPERYEARS GENE TECHNOLOGY CO., LTD. 400 17.2.5 MEDICOVER GENETICS 400 17.2.6 MEDGENOME 401 17.2.7 FULGENT GENETICS 401 17.2.8 INVICTA SP. Z O.O. 402 17.2.9 GENEA PTY LIMITED 402 17.2.10 SCIGENE CORPORATION 403 17.2.11 BIOARRAY S.L. 403 17.2.12 UNIMED BIOTECH (SHANGHAI) CO., LTD. 404 17.2.13 GENEMIND BIOSCIENCES CO., LTD. 404 17.2.14 BERRY GENOMICS 405 17.2.15 BANGKOK GENOMICS INNOVATION 405 18 APPENDIX 406 18.1 DISCUSSION GUIDE 406 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 411 18.3 CUSTOMIZATION OPTIONS 413 18.4 RELATED REPORTS 413 18.5 AUTHOR DETAILS 414
圖表清單 List of Tables & Figures
TABLE 1 PREIMPLANTATION GENETIC TESTING MARKET: INCLUSIONS & EXCLUSIONS 38 TABLE 2 PREIMPLANTATION GENETIC TESTING MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 55 TABLE 3 AVERAGE SELLING PRICE TREND OF PREIMPLANTATION GENETIC TESTING PRODUCTS, BY END USER, 2022−2024 (USD) 65 TABLE 4 AVERAGE SELLING PRICE TREND OF PREIMPLANTATION GENETIC TESTING PRODUCTS, BY KEY PLAYER, 2022–2024 (USD) 65 TABLE 5 AVERAGE SELLING PRICE TREND OF PREIMPLANTATION GENETIC TESTING PRODUCTS, BY PROCEDURE TYPE, 2022−2024 (USD) 67 TABLE 6 AVERAGE SELLING PRICE TREND OF PREIMPLANTATION GENETIC TESTING INSTRUMENTS, BY REGION, 2022–2024 (USD MILLION) 67 TABLE 7 AVERAGE SELLING PRICE MEAN TREND OF PREIMPLANTATION GENETIC TESTING CONSUMABLES, BY REGION, 2022–2024 (USD) 67 TABLE 8 IMPORT DATA FOR HS CODE 3822, BY COUNTRY, 2020–2024 (USD THOUSAND) 69 TABLE 9 EXPORT DATA FOR HS CODE 3822, BY COUNTRY, 2020–2024 (USD THOUSAND) 70 TABLE 10 IMPORT DATA FOR HS CODE 9018, BY COUNTRY, 2020–2024 (USD THOUSAND) 71 TABLE 11 EXPORT DATA FOR HS CODE 9018, BY COUNTRY, 2020–2024 (USD THOUSAND) 72 TABLE 12 PREIMPLANTATION GENETIC TESTING MARKET: ROLE IN ECOSYSTEM 76 TABLE 13 PREIMPLANTATION GENETIC TESTING MARKET: PORTER’S FIVE FORCES 77 TABLE 14 KEY CONFERENCES & EVENTS IN PREIMPLANTATION GENETIC TESTING MARKET: JANUARY 2025–DECEMBER 2026 79 TABLE 15 US-ADJUSTED RECIPROCAL TARIFF RATES 81 TABLE 16 NUMBER OF EXPORTS AND IMPORTS, BY REGION, 2024–2025 (USD MILLION) 82 TABLE 17 KEY PRODUCT-RELATED TARIFF: HS CODES FOR PRODUCTS RELEVANT TO PREIMPLANTATION GENETIC TESTING 83 TABLE 18 CRITICAL COMPONENTS LIKELY EXPOSED TO TARIFF CHANGES 84 TABLE 19 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2014–2024 89 TABLE 20 LIST OF KEY PATENTS IN PREIMPLANTATION GENETIC TESTING MARKET, 2023–2025 91 TABLE 21 KEY PLAYERS IMPLEMENTING AI/GEN AI IN PREIMPLANTATION GENETIC TESTING MARKET 94 TABLE 22 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 96 TABLE 23 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 97 TABLE 24 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 97 TABLE 25 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98 TABLE 26 US: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES 99 TABLE 27 EUROPE: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES 102 TABLE 28 JAPAN: CLASSIFICATION OF IN VITRO DIAGNOSTIC REAGENTS 105 TABLE 29 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 105 TABLE 30 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 106 TABLE 31 VENDOR CERTIFICATIONS: PREIMPLANTATION GENETIC TESTING MARKET 109 TABLE 32 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE 111 TABLE 33 KEY BUYING CRITERIA FOR MAJOR END USERS 112 TABLE 34 PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 115 TABLE 35 PREIMPLANTATION GENETIC TESTING REAGENTS & CONSUMABLES MARKET, BY REGION, 2023–2030 (USD MILLION) 116 TABLE 36 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 116 TABLE 37 EUROPE: PREIMPLANTATION GENETIC TESTING REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 117 TABLE 38 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 117 TABLE 39 LATIN AMERICA: PREIMPLANTATION GENETIC TESTING REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 118 TABLE 40 MIDDLE EAST: PREIMPLANTATION GENETIC TESTING REAGENTS & CONSUMABLES MARKET, BY REGION, 2023–2030 (USD MILLION) 118 TABLE 41 GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 119 TABLE 42 PREIMPLANTATION GENETIC TESTING INSTRUMENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 120 TABLE 43 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 120 TABLE 44 EUROPE: PREIMPLANTATION GENETIC TESTING INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 121 TABLE 45 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 121 TABLE 46 LATIN AMERICA: PREIMPLANTATION GENETIC TESTING INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 122 TABLE 47 MIDDLE EAST: PREIMPLANTATION GENETIC TESTING INSTRUMENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 122 TABLE 48 GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 123 TABLE 49 PREIMPLANTATION GENETIC TESTING SOFTWARE & SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 124 TABLE 50 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING SOFTWARE & SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 124 TABLE 51 EUROPE: PREIMPLANTATION GENETIC TESTING SOFTWARE & SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 52 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING SOFTWARE & SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 53 LATIN AMERICA: PREIMPLANTATION GENETIC TESTING SOFTWARE & SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 54 MIDDLE EAST: PREIMPLANTATION GENETIC TESTING SOFTWARE & SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 126 TABLE 55 GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING SOFTWARE & SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 127 TABLE 56 PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION) 129 TABLE 57 PREIMPLANTATION GENETIC SCREENING MARKET, BY REGION, 2023–2030 (USD MILLION) 130 TABLE 58 NORTH AMERICA: PREIMPLANTATION GENETIC SCREENING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 130 TABLE 59 EUROPE: PREIMPLANTATION GENETIC SCREENING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 131 TABLE 60 ASIA PACIFIC: PREIMPLANTATION GENETIC SCREENING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 131 TABLE 61 LATIN AMERICA: PREIMPLANTATION GENETIC SCREENING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 132 TABLE 62 MIDDLE EAST: PREIMPLANTATION GENETIC SCREENING MARKET, BY REGION, 2023–2030 (USD MILLION) 132 TABLE 63 GCC COUNTRIES: PREIMPLANTATION GENETIC SCREENING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 133 TABLE 64 PREIMPLANTATION GENETIC DIAGNOSIS MARKET, BY REGION, 2023–2030 (USD MILLION) 134 TABLE 65 NORTH AMERICA: PREIMPLANTATION GENETIC DIAGNOSIS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 66 EUROPE: PREIMPLANTATION GENETIC DIAGNOSIS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 67 ASIA PACIFIC: PREIMPLANTATION GENETIC DIAGNOSIS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 68 LATIN AMERICA: PREIMPLANTATION GENETIC DIAGNOSIS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 136 TABLE 69 MIDDLE EAST: PREIMPLANTATION GENETIC DIAGNOSIS MARKET, BY REGION, 2023–2030 (USD MILLION) 136 TABLE 70 GCC COUNTRIES: PREIMPLANTATION GENETIC DIAGNOSIS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 137 TABLE 71 PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 139 TABLE 72 PREIMPLANTATION GENETIC TESTING MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2023–2030 (USD MILLION) 140 TABLE 73 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION) 140 TABLE 74 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 75 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 76 LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION) 142 TABLE 77 MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2023–2030 (USD MILLION) 142 TABLE 78 GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION) 143 TABLE 79 PREIMPLANTATION GENETIC TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2023–2030 (USD MILLION) 144 TABLE 80 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 81 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION) 145 TABLE 82 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION) 145 TABLE 83 LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION) 146 TABLE 84 MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2023–2030 (USD MILLION) 146 TABLE 85 GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 86 PREIMPLANTATION GENETIC TESTING MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2023–2030 (USD MILLION) 148 TABLE 87 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2023–2030 (USD MILLION) 148 TABLE 88 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2023–2030 (USD MILLION) 149 TABLE 89 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2023–2030 (USD MILLION) 149 TABLE 90 LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 91 MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2023–2030 (USD MILLION) 150 TABLE 92 GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2023–2030 (USD MILLION) 151 TABLE 93 PREIMPLANTATION GENETIC TESTING MARKET FOR COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2023–2030 (USD MILLION) 152 TABLE 94 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR COMPARATIVE GENOMIC HYBRIDIZATION, BY COUNTRY, 2023–2030 (USD MILLION) 152 TABLE 95 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR COMPARATIVE GENOMIC HYBRIDIZATION, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 96 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR COMPARATIVE GENOMIC HYBRIDIZATION, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 97 LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR COMPARATIVE GENOMIC HYBRIDIZATION, BY COUNTRY, 2023–2030 (USD MILLION) 154 TABLE 98 MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET FOR COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2023–2030 (USD MILLION) 154 TABLE 99 GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET FOR COMPARATIVE GENOMIC HYBRIDIZATION, BY COUNTRY, 2023–2030 (USD MILLION) 155 TABLE 100 PREIMPLANTATION GENETIC TESTING MARKET FOR SINGLE-NUCLEOTIDE POLYMORPHISM, BY REGION, 2023–2030 (USD MILLION) 156 TABLE 101 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR SINGLE-NUCLEOTIDE POLYMORPHISM, BY COUNTRY, 2023–2030 (USD MILLION) 156 TABLE 102 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR SINGLE-NUCLEOTIDE POLYMORPHISM, BY COUNTRY, 2023–2030 (USD MILLION) 157 TABLE 103 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR SINGLE-NUCLEOTIDE POLYMORPHISM, BY COUNTRY, 2023–2030 (USD MILLION) 157 TABLE 104 LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR SINGLE-NUCLEOTIDE POLYMORPHISM, BY COUNTRY, 2023–2030 (USD MILLION) 158 TABLE 105 MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET FOR SINGLE-NUCLEOTIDE POLYMORPHISM, BY REGION, 2023–2030 (USD MILLION) 158 TABLE 106 GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET FOR SINGLE-NUCLEOTIDE POLYMORPHISM, BY COUNTRY, 2023–2030 (USD MILLION) 159 TABLE 107 PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 161 TABLE 108 PREIMPLANTATION GENETIC TESTING MARKET FOR ANEUPLOIDY, BY REGION, 2023–2030 (USD MILLION) 162 TABLE 109 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR ANEUPLOIDY, BY COUNTRY, 2023–2030 (USD MILLION) 163 TABLE 110 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR ANEUPLOIDY, BY COUNTRY, 2023–2030 (USD MILLION) 163 TABLE 111 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR ANEUPLOIDY, BY COUNTRY, 2023–2030 (USD MILLION) 164 TABLE 112 LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR ANEUPLOIDY, BY COUNTRY, 2023–2030 (USD MILLION) 164 TABLE 113 MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET FOR ANEUPLOIDY, BY REGION, 2023–2030 (USD MILLION) 165 TABLE 114 GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET FOR ANEUPLOIDY, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 115 PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION) 166 TABLE 116 PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY REGION, 2023–2030 (USD MILLION) 166 TABLE 117 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY COUNTRY, 2023–2030 (USD MILLION) 167 TABLE 118 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY COUNTRY, 2023–2030 (USD MILLION) 167 TABLE 119 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY COUNTRY, 2023–2030 (USD MILLION) 168 TABLE 120 LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY COUNTRY, 2023–2030 (USD MILLION) 168 TABLE 121 MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY COUNTRY, 2023–2030 (USD MILLION) 169 TABLE 122 GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY COUNTRY, 2023–2030 (USD MILLION) 169 TABLE 123 STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET FOR TRANSLOCATIONS, BY REGION, 2023–2030 (USD MILLION) 170 TABLE 124 NORTH AMERICA: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET FOR TRANSLOCATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 170 TABLE 125 EUROPE: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET FOR TRANSLOCATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 171 TABLE 126 ASIA PACIFIC: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET FOR TRANSLOCATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 171 TABLE 127 LATIN AMERICA: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET FOR TRANSLOCATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 172 TABLE 128 MIDDLE EAST: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET FOR TRANSLOCATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 172 TABLE 129 GCC COUNTRIES: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET FOR TRANSLOCATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 173 TABLE 130 STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET FOR DELETIONS, BY REGION, 2023–2030 (USD MILLION) 174 TABLE 131 NORTH AMERICA: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET FOR DELETIONS, BY COUNTRY, 2023–2030 (USD MILLION) 174 TABLE 132 EUROPE: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET FOR DELETIONS, BY COUNTRY, 2023–2030 (USD MILLION) 175 TABLE 133 ASIA PACIFIC: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET FOR DELETIONS, BY COUNTRY, 2023–2030 (USD MILLION) 175 TABLE 134 LATIN AMERICA: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET FOR DELETIONS, BY COUNTRY, 2023–2030 (USD MILLION) 176 TABLE 135 MIDDLE EAST: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET FOR DELETIONS, BY COUNTRY, 2023–2030 (USD MILLION) 176 TABLE 136 GCC COUNTRIES: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET FOR DELETIONS, BY COUNTRY, 2023–2030 (USD MILLION) 177 TABLE 137 STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET FOR DUPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 178 TABLE 138 NORTH AMERICA: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET FOR DUPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 178 TABLE 139 EUROPE: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET FOR DUPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 179 TABLE 140 ASIA PACIFIC: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET FOR DUPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 179 TABLE 141 LATIN AMERICA: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET FOR DUPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 180 TABLE 142 MIDDLE EAST: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET FOR DUPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 180 TABLE 143 GCC COUNTRIES: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET FOR DUPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 181 TABLE 144 STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET FOR INVERSIONS, BY REGION, 2023–2030 (USD MILLION) 182 TABLE 145 NORTH AMERICA: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET FOR INVERSIONS, BY COUNTRY, 2023–2030 (USD MILLION) 182 TABLE 146 EUROPE: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET FOR INVERSIONS, BY COUNTRY, 2023–2030 (USD MILLION) 183 TABLE 147 ASIA PACIFIC: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET FOR INVERSIONS, BY COUNTRY, 2023–2030 (USD MILLION) 183 TABLE 148 LATIN AMERICA: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET INVERSIONS, BY COUNTRY, 2023–2030 (USD MILLION) 184 TABLE 149 MIDDLE EAST: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET FOR INVERSIONS, BY COUNTRY, 2023–2030 (USD MILLION) 184 TABLE 150 GCC COUNTRIES: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET FOR INVERSIONS, BY COUNTRY, 2023–2030 (USD MILLION) 185 TABLE 151 PREIMPLANTATION GENETIC TESTING MARKET FOR SINGLE GENE DISORDERS, BY REGION, 2023–2030 (USD MILLION) 186 TABLE 152 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR SINGLE GENE DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 186 TABLE 153 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR SINGLE GENE DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 187 TABLE 154 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR SINGLE GENE DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 187 TABLE 155 LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR SINGLE GENE DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 188 TABLE 156 MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET FOR SINGLE GENE DISORDERS, BY REGION, 2023–2030 (USD MILLION) 188 TABLE 157 GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET FOR SINGLE GENE DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 189 TABLE 158 PREIMPLANTATION GENETIC TESTING MARKET FOR X-LINKED DISORDERS, BY REGION, 2023–2030 (USD MILLION) 190 TABLE 159 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR X-LINKED DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 190 TABLE 160 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR X-LINKED DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 191 TABLE 161 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR X-LINKED DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 191 TABLE 162 LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR X-LINKED DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 192 TABLE 163 MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET FOR X-LINKED DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 192 TABLE 164 GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET FOR X-LINKED DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 193 TABLE 165 PREIMPLANTATION GENETIC TESTING MARKET FOR HLA TYPING, BY REGION, 2023–2030 (USD MILLION) 194 TABLE 166 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR HLA TYPING, BY COUNTRY, 2023–2030 (USD MILLION) 194 TABLE 167 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR HLA TYPING, BY COUNTRY, 2023–2030 (USD MILLION) 195 TABLE 168 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR HLA TYPING, BY COUNTRY, 2023–2030 (USD MILLION) 195 TABLE 169 LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR HLA TYPING, BY COUNTRY, 2023–2030 (USD MILLION) 196 TABLE 170 MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET FOR HLA TYPING, BY COUNTRY, 2023–2030 (USD MILLION) 196 TABLE 171 GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET FOR HLA TYPING, BY COUNTRY, 2023–2030 (USD MILLION) 197 TABLE 172 PREIMPLANTATION GENETIC TESTING MARKET FOR GENDER IDENTIFICATION, BY REGION, 2023–2030 (USD MILLION) 198 TABLE 173 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR GENDER IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION) 198 TABLE 174 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR GENDER IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION) 199 TABLE 175 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR GENDER IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION) 199 TABLE 176 LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR GENDER IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION) 200 TABLE 177 MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET FOR GENDER IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION) 200 TABLE 178 GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET FOR GENDER IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION) 201 TABLE 179 PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2023–2030 (USD MILLION) 203 TABLE 180 PREIMPLANTATION GENETIC TESTING MARKET FOR FRESH NON-DONOR, BY REGION, 2023–2030 (USD MILLION) 204 TABLE 181 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR FRESH NON-DONOR, BY COUNTRY, 2023–2030 (USD MILLION) 204 TABLE 182 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR FRESH NON-DONOR, BY COUNTRY, 2023–2030 (USD MILLION) 205 TABLE 183 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR FRESH NON-DONOR, BY COUNTRY, 2023–2030 (USD MILLION) 205 TABLE 184 LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR FRESH NON-DONOR, BY COUNTRY, 2023–2030 (USD MILLION) 206 TABLE 185 MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET FOR FRESH NON-DONOR, BY REGION, 2023–2030 (USD MILLION) 206 TABLE 186 GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET FOR FRESH NON-DONOR, BY COUNTRY, 2023–2030 (USD MILLION) 207 TABLE 187 PREIMPLANTATION GENETIC TESTING MARKET FOR FROZEN NON-DONOR, BY REGION, 2023–2030 (USD MILLION) 208 TABLE 188 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR FROZEN NON-DONOR, BY COUNTRY, 2023–2030 (USD MILLION) 208 TABLE 189 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR FROZEN NON-DONOR, BY COUNTRY, 2023–2030 (USD MILLION) 209 TABLE 190 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR FROZEN NON-DONOR, BY COUNTRY, 2023–2030 (USD MILLION) 209 TABLE 191 LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR FROZEN NON-DONOR, BY COUNTRY, 2023–2030 (USD MILLION) 210 TABLE 192 MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET FOR FROZEN NON-DONOR, BY REGION, 2023–2030 (USD MILLION) 210 TABLE 193 GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET FOR FROZEN NON-DONOR, SBY COUNTRY, 2023–2030 (USD MILLION) 211 TABLE 194 PREIMPLANTATION GENETIC TESTING MARKET FOR FRESH DONOR, BY REGION, 2023–2030 (USD MILLION) 212 TABLE 195 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR FRESH DONOR, BY COUNTRY, 2023–2030 (USD MILLION) 212 TABLE 196 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR FRESH DONOR, BY COUNTRY, 2023–2030 (USD MILLION) 213 TABLE 197 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR FRESH DONOR, BY COUNTRY, 2023–2030 (USD MILLION) 213 TABLE 198 LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR FRESH DONOR, BY COUNTRY, 2023–2030 (USD MILLION) 214 TABLE 199 MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET FOR FRESH DONOR, BY REGION, 2023–2030 (USD MILLION) 214 TABLE 200 GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET FOR FRESH DONOR, BY COUNTRY, 2023–2030 (USD MILLION) 215 TABLE 201 PREIMPLANTATION GENETIC TESTING MARKET FOR FROZEN DONOR, BY REGION, 2023–2030 (USD MILLION) 216 TABLE 202 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR FROZEN DONOR, BY COUNTRY, 2023–2030 (USD MILLION) 216 TABLE 203 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR FROZEN DONOR, BY COUNTRY, 2023–2030 (USD MILLION) 217 TABLE 204 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR FROZEN DONOR, BY COUNTRY, 2023–2030 (USD MILLION) 217 TABLE 205 LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR FROZEN DONOR, BY COUNTRY, 2023–2030 (USD MILLION) 218 TABLE 206 MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET FOR FROZEN DONOR, BY REGION, 2023–2030 (USD MILLION) 218 TABLE 207 GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET FOR FROZEN DONOR, BY COUNTRY, 2023–2030 (USD MILLION) 219 TABLE 208 PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030 (USD MILLION) 221 TABLE 209 PREIMPLANTATION GENETIC TESTING MARKET FOR FERTILITY CLINICS, BY REGION, 2023–2030 (USD MILLION) 222 TABLE 210 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR FERTILITY CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 222 TABLE 211 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR FERTILITY CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 223 TABLE 212 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR FERTILITY CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 223 TABLE 213 LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR FERTILITY CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 224 TABLE 214 MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET FOR FERTILITY CLINICS, BY REGION, 2023–2030 (USD MILLION) 224 TABLE 215 GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET FOR FERTILITY CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 225 TABLE 216 PREIMPLANTATION GENETIC TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2023–2030 (USD MILLION) 226 TABLE 217 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 226 TABLE 218 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 227 TABLE 219 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 227 TABLE 220 LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 228 TABLE 221 MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2023–2030 (USD MILLION) 228 TABLE 222 GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 229 TABLE 223 PREIMPLANTATION GENETIC TESTING MARKET FOR HOSPITALS, BY REGION, 2023–2030 (USD MILLION) 230 TABLE 224 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 230 TABLE 225 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 231 TABLE 226 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 231 TABLE 227 LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 232 TABLE 228 MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET FOR HOSPITALS, BY REGION, 2023–2030 (USD MILLION) 232 TABLE 229 GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 233 TABLE 230 PREIMPLANTATION GENETIC TESTING MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION) 234 TABLE 231 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 234 TABLE 232 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 235 TABLE 233 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 235 TABLE 234 LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 236 TABLE 235 MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION) 236 TABLE 236 GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 237 TABLE 237 PREIMPLANTATION GENETIC TESTING MARKET, BY REGION, 2023–2030 (USD MILLION) 239 TABLE 238 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 240 TABLE 239 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 241 TABLE 240 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION) 241 TABLE 241 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 242 TABLE 242 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 242 TABLE 243 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION) 243 TABLE 244 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2023–2030 (USD MILLION) 243 TABLE 245 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030 (USD MILLION) 244 TABLE 246 US: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 245 TABLE 247 US: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION) 245 TABLE 248 US: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 246 TABLE 249 US: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 246 TABLE 250 US: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION) 247 TABLE 251 US: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2023–2030 (USD MILLION) 247 TABLE 252 US: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030 (USD MILLION) 248 TABLE 253 CANADA: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 249 TABLE 254 CANADA: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION) 249 TABLE 255 CANADA: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 250 TABLE 256 CANADA: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 250 TABLE 257 CANADA: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION) 251 TABLE 258 CANADA: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2023–2030 (USD MILLION) 251 TABLE 259 CANADA: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030 (USD MILLION) 252 TABLE 260 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 253 TABLE 261 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 253 TABLE 262 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION) 254 TABLE 263 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 254 TABLE 264 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 255 TABLE 265 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION) 255 TABLE 266 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2023–2030 (USD MILLION) 256 TABLE 267 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030 (USD MILLION) 256 TABLE 268 GERMANY: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 257 TABLE 269 GERMANY: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION) 258 TABLE 270 GERMANY: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 258 TABLE 271 GERMANY: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 259 TABLE 272 GERMANY: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION) 259 TABLE 273 GERMANY: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2023–2030 (USD MILLION) 260 TABLE 274 GERMANY: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030 (USD MILLION) 260 TABLE 275 UK: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 261 TABLE 276 UK: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION) 262 TABLE 277 UK: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 262 TABLE 278 UK: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 263 TABLE 279 UK: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION) 263 TABLE 280 UK: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2023–2030 (USD MILLION) 264 TABLE 281 UK: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030 (USD MILLION) 264 TABLE 282 FRANCE: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 265 TABLE 283 FRANCE: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION) 266 TABLE 284 FRANCE: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 266 TABLE 285 FRANCE: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 267 TABLE 286 FRANCE: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION) 267 TABLE 287 FRANCE: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2023–2030 (USD MILLION) 268 TABLE 288 FRANCE: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030 (USD MILLION) 268 TABLE 289 ITALY: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 269 TABLE 290 ITALY: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION) 269 TABLE 291 ITALY: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 270 TABLE 292 ITALY: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 270 TABLE 293 ITALY: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION) 271 TABLE 294 ITALY: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2023–2030 (USD MILLION) 271 TABLE 295 ITALY: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030 (USD MILLION) 272 TABLE 296 SPAIN: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 273 TABLE 297 SPAIN: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION) 273 TABLE 298 SPAIN: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 274 TABLE 299 SPAIN: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 274 TABLE 300 SPAIN: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION) 275 TABLE 301 SPAIN: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2023–2030 (USD MILLION) 275 TABLE 302 SPAIN: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030 (USD MILLION) 276 TABLE 303 REST OF EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 277 TABLE 304 REST OF EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION) 277 TABLE 305 REST OF EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 278 TABLE 306 REST OF EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 278 TABLE 307 REST OF EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION) 279 TABLE 308 REST OF EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2023–2030 (USD MILLION) 279 TABLE 309 REST OF EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030 (USD MILLION) 280 TABLE 310 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 282 TABLE 311 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 282 TABLE 312 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION) 283 TABLE 313 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 283 TABLE 314 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 284 TABLE 315 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION) 284 TABLE 316 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2023–2030 (USD MILLION) 285 TABLE 317 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030 (USD MILLION) 285 TABLE 318 CHINA: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 286 TABLE 319 CHINA: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION) 286 TABLE 320 CHINA: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 287 TABLE 321 CHINA: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 287 TABLE 322 CHINA: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION) 288 TABLE 323 CHINA: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2023–2030 (USD MILLION) 288 TABLE 324 CHINA: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030 (USD MILLION) 289 TABLE 325 JAPAN: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 290 TABLE 326 JAPAN: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION) 290 TABLE 327 JAPAN: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 291 TABLE 328 JAPAN: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 291 TABLE 329 JAPAN: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION) 292 TABLE 330 JAPAN: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2023–2030 (USD MILLION) 292 TABLE 331 JAPAN: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030 (USD MILLION) 293 TABLE 332 INDIA: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 294 TABLE 333 INDIA: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION) 294 TABLE 334 INDIA: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 295 TABLE 335 INDIA: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 295 TABLE 336 INDIA: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION) 296 TABLE 337 INDIA: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2023–2030 (USD MILLION) 296 TABLE 338 INDIA: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030 (USD MILLION) 297 TABLE 339 AUSTRALIA: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 298 TABLE 340 AUSTRALIA: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION) 298 TABLE 341 AUSTRALIA: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 299 TABLE 342 AUSTRALIA: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 299 TABLE 343 AUSTRALIA: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION) 300 TABLE 344 AUSTRALIA: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2023–2030 (USD MILLION) 300 TABLE 345 AUSTRALIA: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030 (USD MILLION) 301 TABLE 346 SOUTH KOREA: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 302 TABLE 347 SOUTH KOREA: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION) 302 TABLE 348 SOUTH KOREA: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 303 TABLE 349 SOUTH KOREA: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 303 TABLE 350 SOUTH KOREA: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION) 304 TABLE 351 SOUTH KOREA: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2023–2030 (USD MILLION) 304 TABLE 352 SOUTH KOREA: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030 (USD MILLION) 305 TABLE 353 REST OF ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 306 TABLE 354 REST OF ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION) 306 TABLE 355 REST OF ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 307 TABLE 356 REST OF ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 307 TABLE 357 REST OF ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION) 308 TABLE 358 REST OF ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2023–2030 (USD MILLION) 308 TABLE 359 REST OF ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030 (USD MILLION) 309 TABLE 360 LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 309 TABLE 361 LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 310 TABLE 362 LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION) 310 TABLE 363 LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 311 TABLE 364 LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 311 TABLE 365 LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION) 312 TABLE 366 LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2023–2030 (USD MILLION) 312 TABLE 367 LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030 (USD MILLION) 313 TABLE 368 BRAZIL: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 314 TABLE 369 BRAZIL: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION) 314 TABLE 370 BRAZIL: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 315 TABLE 371 BRAZIL: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 315 TABLE 372 BRAZIL: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION) 316 TABLE 373 BRAZIL: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2023–2030 (USD MILLION) 316 TABLE 374 BRAZIL: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030 (USD MILLION) 317 TABLE 375 MEXICO: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 318 TABLE 376 MEXICO: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION) 318 TABLE 377 MEXICO: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 319 TABLE 378 MEXICO: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 319 TABLE 379 MEXICO: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION) 320 TABLE 380 MEXICO: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2023–2030 (USD MILLION) 320 TABLE 381 MEXICO: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030 (USD MILLION) 321 TABLE 382 REST OF LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 322 TABLE 383 REST OF LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION) 322 TABLE 384 REST OF LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 323 TABLE 385 REST OF LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 323 TABLE 386 REST OF LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION) 324 TABLE 387 REST OF LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2023–2030 (USD MILLION) 324 TABLE 388 REST OF LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030 (USD MILLION) 325 TABLE 389 MIDDLE EAST: KEY MACROINDICATORS 325 TABLE 390 MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET, BY REGION, 2023–2030 (USD MILLION) 326 TABLE 391 MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 326 TABLE 392 MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION) 327 TABLE 393 MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 327 TABLE 394 MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 328 TABLE 395 MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION) 328 TABLE 396 MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2023–2030 (USD MILLION) 329 TABLE 397 MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030 (USD MILLION) 329 TABLE 398 GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 330 TABLE 399 GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 330 TABLE 400 GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION) 331 TABLE 401 GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 331 TABLE 402 GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 332 TABLE 403 GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION) 332 TABLE 404 GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2023–2030 (USD MILLION) 333 TABLE 405 GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030 (USD MILLION) 333 TABLE 406 KINGDOM OF SAUDI ARABIA: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 334 TABLE 407 KINGDOM OF SAUDI ARABIA: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION) 335 TABLE 408 KINGDOM OF SAUDI ARABIA: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 335 TABLE 409 KINGDOM OF SAUDI ARABIA: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 336 TABLE 410 KINGDOM OF SAUDI ARABIA: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION) 336 TABLE 411 KINGDOM OF SAUDI ARABIA: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2023–2030 (USD MILLION) 337 TABLE 412 KINGDOM OF SAUDI ARABIA: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030 (USD MILLION) 337 TABLE 413 UAE: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 338 TABLE 414 UAE: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION) 339 TABLE 415 UAE: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 339 TABLE 416 UAE: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 340 TABLE 417 UAE: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION) 340 TABLE 418 UAE: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2023–2030 (USD MILLION) 341 TABLE 419 UAE: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030 (USD MILLION) 341 TABLE 420 REST OF GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 342 TABLE 421 REST OF GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION) 343 TABLE 422 REST OF GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 343 TABLE 423 REST OF GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 344 TABLE 424 REST OF GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION) 344 TABLE 425 REST OF GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2023–2030 (USD MILLION) 345 TABLE 426 REST OF GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030 (USD MILLION) 345 TABLE 427 REST OF MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 346 TABLE 428 REST OF MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION) 346 TABLE 429 REST OF MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 347 TABLE 430 REST OF MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 347 TABLE 431 REST OF MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION) 348 TABLE 432 REST OF MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2023–2030 (USD MILLION) 348 TABLE 433 REST OF MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030 (USD MILLION) 349 TABLE 434 AFRICA: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 350 TABLE 435 AFRICA: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION) 350 TABLE 436 AFRICA: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 351 TABLE 437 AFRICA: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 351 TABLE 438 AFRICA: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION) 352 TABLE 439 AFRICA: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2023–2030 (USD MILLION) 352 TABLE 440 AFRICA: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030 (USD MILLION) 353 TABLE 441 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN PREIMPLANTATION GENETIC TESTING MARKET, JANUARY 2022-OCTOBER 2025 354 TABLE 442 PREIMPLANTATION GENETIC TESTING MARKET: DEGREE OF COMPETITION 356 TABLE 443 PREIMPLANTATION GENETIC TESTING MARKET: REGION FOOTPRINT 363 TABLE 444 PREIMPLANTATION GENETIC TESTING MARKET: PRODUCT & SERVICE FOOTPRINT 363 TABLE 445 PREIMPLANTATION GENETIC TESTING MARKET: TECHNOLOGY FOOTPRINT 364 TABLE 446 PREIMPLANTATION GENETIC TESTING MARKET: APPLICATION FOOTPRINT 365 TABLE 447 PREIMPLANTATION GENETIC TESTING MARKET: DETAILED LIST OF KEY STARTUPS/SMES 368 TABLE 448 PREIMPLANTATION GENETIC TESTING MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, BY PRODUCT & SERVICE AND REGION 370 TABLE 449 PREIMPLANTATION GENETIC TESTING MARKET: PRODUCT LAUNCHES, JANUARY 2022–OCTOBER 2025 371 TABLE 450 PREIMPLANTATION GENETIC TESTING MARKET: DEALS, JANUARY 2022–OCTOBER 2025 371 TABLE 451 PREIMPLANTATION GENETIC TESTING MARKET: EXPANSIONS, JANUARY 2022–OCTOBER 2025 372 TABLE 452 ILLUMINA, INC.: COMPANY OVERVIEW 373 TABLE 453 ILLUMINA, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 374 TABLE 454 ILLUMINA, INC.: DEALS, JANUARY 2022–OCTOBER 2025 375 TABLE 455 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 376 TABLE 456 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 377 TABLE 457 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES, JANUARY 2022–OCTOBER 2025 378 TABLE 458 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 379 TABLE 459 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 380 TABLE 460 REVVITY: COMPANY OVERVIEW 382 TABLE 461 REVVITY: PRODUCTS/SERVICES/SOLUTIONS OFFERED 383 TABLE 462 COOPERCOMPANIES: COMPANY OVERVIEW 385 TABLE 463 COOPERCOMPANIES: PRODUCTS/SERVICES/SOLUTIONS OFFERED 386 TABLE 464 ABBOTT: COMPANY OVERVIEW 388 TABLE 465 ABBOTT: PRODUCTS/SERVICES/SOLUTIONS OFFERED 389 TABLE 466 TAKARA BIO INC.: COMPANY OVERVIEW 390 TABLE 467 TAKARA BIO INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 391 TABLE 468 QIAGEN: COMPANY OVERVIEW 392 TABLE 469 QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED 393 TABLE 470 VITROLIFE: COMPANY OVERVIEW 394 TABLE 471 VITROLIFE: PRODUCTS/SERVICES/SOLUTIONS OFFERED 395 TABLE 472 OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY OVERVIEW 396 TABLE 473 OXFORD NANOPORE TECHNOLOGIES PLC: PRODUCTS/SERVICES/ SOLUTIONS OFFERED 397 TABLE 474 OXFORD NANOPORE TECHNOLOGIES PLC: EXPANSIONS, JANUARY 2022–OCTOBER 2025 398 TABLE 475 OXFORD GENE TEHNOLOGY IP LIMITED: COMPANY OVERVIEW 398 TABLE 476 YIKON GENOMICS: COMPANY OVERVIEW 399 TABLE 477 SHIVA SCIENTIFIC: COMPANY OVERVIEW 399 TABLE 478 NANJING SUPERYEARS GENE TECHNOLOGY CO., LTD.: COMPANY OVERVIEW 400 TABLE 479 MEDICOVER GENETICS: COMPANY OVERVIEW 400 TABLE 480 MEDGENOME: COMPANY OVERVIEW 401 TABLE 481 FULGENT GENETICS: COMPANY OVERVIEW 401 TABLE 482 INVICTA SP. Z O.O.: COMPANY OVERVIEW 402 TABLE 483 GENEA PTY LIMITED: COMPANY OVERVIEW 402 TABLE 484 SCIGENE CORPORATION: COMPANY OVERVIEW 403 TABLE 485 BIOARRAY S.L.: COMPANY OVERVIEW 403 TABLE 486 UNIMED BIOTECH (SHANGHAI) CO., LTD.: COMPANY OVERVIEW 404 TABLE 487 GENEMIND BIOSCIENCES CO., LTD.: COMPANY OVERVIEW 404 TABLE 488 BERRY GENOMICS: COMPANY OVERVIEW 405 TABLE 489 BANGKOK GENOMICS INNOVATION: COMPANY OVERVIEW 405 FIGURE 1 PREIMPLANTATION GENETIC TESTING MARKET SEGMENTATION & REGIONAL SCOPE 37 FIGURE 2 PREIMPLANTATION GENETIC TESTING MARKET: YEARS CONSIDERED 38 FIGURE 3 PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 (USD MILLION) 41 FIGURE 4 PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2025 VS. 2030 (USD MILLION) 42 FIGURE 5 PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION) 43 FIGURE 6 PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 44 FIGURE 7 PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2025 VS. 2030 (USD MILLION) 45 FIGURE 8 PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 46 FIGURE 9 REGIONAL ANALYSIS: PREIMPLANTATION GENETIC TESTING MARKET 47 FIGURE 10 DECLINING FERTILITY RATES TO PROPEL MARKET GROWTH 50 FIGURE 11 US AND REAGENTS & CONSUMABLES COMMANDED LARGEST NORTH AMERICAN MARKET SHARE IN 2024 51 FIGURE 12 ASIA PACIFIC TO BE FASTEST-GROWING MARKET FROM 2025 TO 2030 52 FIGURE 13 REAGENTS & CONSUMABLES TO DOMINATE MARKET DURING STUDY PERIOD 53 FIGURE 14 FERTILITY CLINICS ACCOUNTED FOR LARGEST MARKET SHARE IN 2024 53 FIGURE 15 PREIMPLANTATION GENETIC TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 54 FIGURE 16 PREIMPLANTATION GENETIC TESTING MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 62 FIGURE 17 AVERAGE SELLING PRICE TREND OF PREIMPLANTATION GENETIC TESTING INSTRUMENTS, BY KEY PLAYER, 2024 (USD) 66 FIGURE 18 AVERAGE SELLING PRICE TREND OF PREIMPLANTATION GENETIC TESTING CONSUMABLES, BY KEY PLAYER, 2024 (USD) 66 FIGURE 19 AVERAGE SELLING PRICE TREND OF PREIMPLANTATION GENETIC TESTING INSTRUMENTS, BY REGION, 2024 (USD MILLION) 68 FIGURE 20 AVERAGE SELLING PRICE TREND OF PREIMPLANTATION GENETIC TESTING CONSUMABLES, BY REGION, 2024 (USD MILLION) 68 FIGURE 21 PREIMPLANTATION GENETIC TESTING MARKET: VALUE CHAIN ANALYSIS 73 FIGURE 22 PREIMPLANTATION GENETIC TESTING MARKET: ECOSYSTEM ANALYSIS 75 FIGURE 23 PREIMPLANTATION GENETIC TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS 77 FIGURE 24 FUNDING AND NUMBER OF DEALS IN PREIMPLANTATION GENETIC TESTING MARKET, 2022–2025 (USD MILLION) 80 FIGURE 25 PATENT APPLICATIONS IN PREIMPLANTATION GENETIC TESTING MARKET, JANUARY 2014-DECEMBER 2024 90 FIGURE 26 IMPACT OF AI/GEN AI ON PREIMPLANTATION GENETIC TESTING MARKET 93 FIGURE 27 US: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 100 FIGURE 28 CANADA: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 101 FIGURE 29 EUROPE: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 103 FIGURE 30 JAPAN: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 104 FIGURE 31 INDIA: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 107 FIGURE 32 BRAZIL: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 108 FIGURE 33 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE 110 FIGURE 34 KEY BUYING CRITERIA FOR MAJOR END USERS 111 FIGURE 35 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET SNAPSHOT 240 FIGURE 36 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET SNAPSHOT 281 FIGURE 37 REVENUE ANALYSIS OF KEY PLAYERS IN PREIMPLANTATION GENETIC TESTING MARKET, 2020–2024 (USD MILLION) 355 FIGURE 38 MARKET SHARE ANALYSIS OF KEY PLAYERS IN PREIMPLANTATION GENETIC TESTING MARKET (2024) 356 FIGURE 39 EV/EBITDA OF KEY VENDORS 358 FIGURE 40 YEAR-TO-DATE (YTD) PRICE, TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 358 FIGURE 41 PREIMPLANTATION GENETIC TESTING MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 359 FIGURE 42 PREIMPLANTATION GENETIC TESTING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 361 FIGURE 43 PREIMPLANTATION GENETIC TESTING MARKET: COMPANY FOOTPRINT 362 FIGURE 44 PREIMPLANTATION GENETIC TESTING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 367 FIGURE 45 ILLUMINA, INC.: COMPANY SNAPSHOT 374 FIGURE 46 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT 377 FIGURE 47 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT 380 FIGURE 48 REVVITY: COMPANY SNAPSHOT 383 FIGURE 49 COOPERCOMPANIES: COMPANY SNAPSHOT 386 FIGURE 50 ABBOTT: COMPANY SNAPSHOT 389 FIGURE 51 TAKARA BIO INC.: COMPANY SNAPSHOT 391 FIGURE 52 QIAGEN: COMPANY SNAPSHOT 393 FIGURE 53 VITROLIFE: COMPANY SNAPSHOT 395 FIGURE 54 OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY SNAPSHOT 397

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們